{
  "data": {
    "id": "stat_V2JYK200N2K5Z3HSF7J660P114",
    "url": "https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114",
    "indicator": {
      "slug": "new-drugs-approved-after-clinical-trials-cn-registration-category",
      "name": "New drugs approved for marketing after clinical trials (China registration category)",
      "definition": "Number of drugs in China's \"new drug\" registration category (innovative and improved new drugs, including TCM) approved for marketing after clinical trials, as reported by the NMPA Center for Drug Evaluation."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "period": {
      "start": "2025-01-01",
      "end": "2025-12-31",
      "type": "year"
    },
    "value": 248,
    "value_text": "248个",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "National Healthcare Security Administration",
      "org_short_name": "NHSA",
      "org_url": "https://www.nhsa.gov.cn",
      "org_tier": 1,
      "document_title": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升",
      "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html",
      "document_type": "press_release",
      "locator": "试验包括新药临床试验和生物等效性试验",
      "quote": "国家药监局药审中心副主任杨志敏则表示，2025年，我国共有248个新药通过临床试验获批上市，涵盖了抗肿瘤、内分泌、精神障碍等18个适应症领域。",
      "published_date": null,
      "accessed_at": "2026-09-17",
      "license": "see-source",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "editorial:evidence-check-v1:2026-09-26",
    "verified_at": "2026-09-26T15:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_Z2KY4SRVRS4V0XV5GA0GNYZG8F",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "National Healthcare Security Administration. (2025). 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114",
      "bibtex": "@misc{nhsa2025drugs60p114,\n  author       = {{National Healthcare Security Administration}},\n  title        = {从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}"
    },
    "updated_at": "2026-09-26T14:11:11.153Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}